EHA 2026: vídeos e entrevistas

233 vídeos do EHA 2026 publicados por ABHH, ASH, EHA, Oncology Brothers, VJHemOnc. Atualizado em 20/11/2026.

Ver no OncoTV com filtros

How to Improve Equity and Inclusion in Hematology: EHA2026 Diversity, Equity and Inclusion AwardEHA · 02/10/2026 · 14:56Advancing Adult ALL Care in Europe: EHA2026 Clinical Excellence AwardEHA · 25/09/2026 · 20:42What Can We Learn About AML from Clonal Haematopoiesis? | EHA 2026 Research Excellence AwardEHA · 18/09/2026 · 21:32Improving MPNs management: EHA2026 Lifetime Achievement AwardEHA · 15/09/2026 · 21:11ASH Clinical News: July 2026 From the Desk Of...ASH · 15/07/2026 · 4:55Patterns of infection following next-generation B-cell-depleting immunotherapies for NHLVJHemOnc · 14/07/2026 · 6:19 · apoio da indústriaEHA2026 Leukemia Highlights: OPTI-AML, KOMET-007, SENTRYOncology Brothers · 13/07/2026 · 15:43 · apoio da indústriaOptimizing diagnosis and treatment of NK/T-cell lymphomaVJHemOnc · 10/07/2026 · 1:59 · apoio da indústriaPhase II atezolizumab shows durable responses in relapsed NK/T-cell lymphomaVJHemOnc · 10/07/2026 · 2:18 · apoio da indústriaThe evolving role of immunotherapy and frontline treatment strategies in DLBCLVJHemOnc · 10/07/2026 · 2:06 · apoio da indústriaReflecting on progress in MPN research and care: a lifetime perspectiveVJHemOnc · 09/07/2026 · 2:01 · apoio da indústriaHealth-related QoL in patients with high-risk APL treated with arsenic trioxide: APOLLO trialVJHemOnc · 09/07/2026 · 1:03 · apoio da indústriaNon-biopsy diagnostic strategies for primary CNS lymphomaVJHemOnc · 08/07/2026 · 1:12 · apoio da indústriaDiagnosing PCNSL: key considerations and assessing for vitreoretinal involvementVJHemOnc · 08/07/2026 · 1:31 · apoio da indústriaThe future of myeloma therapy: moving toward safer frontline immunotherapy approachesVJHemOnc · 07/07/2026 · 1:32 · apoio da indústriaPreserving kidney function in myeloma: impact of melflufen therapyVJHemOnc · 07/07/2026 · 3:02 · apoio da indústriaInsights from the AIEOP-BFM ALL trial: could blinatumomab replace high-dose chemotherapy in HR ALL?VJHemOnc · 07/07/2026 · 1:48 · apoio da indústriaAddressing underrecognized symptoms and quality-of-life issues in hematologic malignanciesVJHemOnc · 07/07/2026 · 2:25 · apoio da indústriaQ-TWiST analysis from the QUANTUM-First trial: evaluating quality-adjusted survival in AMLVJHemOnc · 07/07/2026 · 1:46 · apoio da indústriaEmerging BTK inhibitor combination strategies being explored in CLLVJHemOnc · 07/07/2026 · 2:31 · apoio da indústriaThe future of precision medicine in MDS: genomic profiling and venetoclax-based strategiesVJHemOnc · 07/07/2026 · 1:55 · apoio da indústriaGene-targeted treatments of hemoglobinopathiesEHA · 06/07/2026 · 3:42Bleeding disorders: from replacing to balancingEHA · 06/07/2026 · 2:54Epigenetics in hematologic malignant (and non-malignant) diseasesEHA · 06/07/2026 · 4:28Using new agents for lymphoid neoplasms in clinical practiceEHA · 06/07/2026 · 4:31AI real-world impact in hematology: hype or hope?EHA · 06/07/2026 · 3:55Toward a personalized therapeutic approach for patients with chronic myeloid malignanciesEHA · 06/07/2026 · 4:32HSC: The lifelong importance of the niche in health and diseaseEHA · 06/07/2026 · 2:42Multiple myeloma: navigating the what, when, and who of treatmentEHA · 06/07/2026 · 2:55Targeted agents in AML: from induction to long-term maintenance and resistanceEHA · 06/07/2026 · 6:23Complement-targeted treatments in hematologyEHA · 06/07/2026 · 5:14CD22-directed CAR-T for NHL subtypes: toxicity and sequencing insightsVJHemOnc · 06/07/2026 · 1:21 · apoio da indústriaEmerging third-generation BTK-targeted therapies for CLL: overcoming BTK resistanceVJHemOnc · 06/07/2026 · 1:22 · apoio da indústriaFixed-duration dose-reduced ibrutinib plus venetoclax: importance of toxicity reduction in CLLVJHemOnc · 06/07/2026 · 1:11 · apoio da indústriaAdvice for community oncologists on managing patients with HL: when to refer to a specialist centerVJHemOnc · 06/07/2026 · 1:42 · apoio da indústriaUK insights into how brentuximab vedotin and PD-1 inhibitors are currently sequenced for relapsed HLVJHemOnc · 06/07/2026 · 2:36 · apoio da indústriaInsights into the evolving treatment paradigm for myelofibrosis beyond spleen and symptom controlVJHemOnc · 06/07/2026 · 1:16 · apoio da indústriaINDEPENDENCE trial: luspatercept in patients with myelofibrosis and anemia on JAK2 inhibitor therapyVJHemOnc · 06/07/2026 · 1:22 · apoio da indústriaInsights into the evolving treatment landscape for MPNs: current state and future directionsVJHemOnc · 06/07/2026 · 2:22 · apoio da indústriaKey advances shaping frontline treatment for AMLVJHemOnc · 06/07/2026 · 1:19 · apoio da indústriaEHA2026 Lymphoma Highlights: frontMIND, POLAR-BEAR, HD-MTX for CNS Lymphoma, EPCORE FL-1Oncology Brothers · 06/07/2026 · 18:05 · apoio da indústriaDoes MRD-guided therapy have potential in CLL?VJHemOnc · 03/07/2026 · 1:02 · apoio da indústriaEmerging treatments for patients with CLL previously exposed to BTK inhibitors and venetoclaxVJHemOnc · 03/07/2026 · 1:11 · apoio da indústriaImmune dysregulation in ITP and warm AIHAVJHemOnc · 03/07/2026 · 1:47 · apoio da indústriaCombination therapies in myelofibrosisVJHemOnc · 03/07/2026 · 1:55 · apoio da indústriaResults from the EPO-Pretar trial: impact of early vs delayed ESA initiation in patients with LR-MDSVJHemOnc · 03/07/2026 · 5:03 · apoio da indústriaBarriers to implementing CTCs in clinical practiceVJHemOnc · 03/07/2026 · 1:19 · apoio da indústriaCTCs as a prognostic biomarker in multiple myelomaVJHemOnc · 03/07/2026 · 1:40 · apoio da indústriaMRD assessment and biologic risk stratification shape personalized care in ALLVJHemOnc · 03/07/2026 · 3:25 · apoio da indústriaThe evolving role of JAK inhibitors in myelofibrosisVJHemOnc · 03/07/2026 · 1:37 · apoio da indústriaRare driver mutations could refine diagnosis and management of myeloproliferative neoplasmsVJHemOnc · 03/07/2026 · 1:31 · apoio da indústriaPonatinib consolidation may improve second treatment-free remission in CMLVJHemOnc · 03/07/2026 · 1:10 · apoio da indústriaBest practices for safely delivering bispecific antibodies in lymphomaVJHemOnc · 03/07/2026 · 6:00 · apoio da indústriaReal-world data support bispecific antibodies in large B-cell lymphomaVJHemOnc · 03/07/2026 · 3:22 · apoio da indústriaSelecting the right treatment for relapsed diffuse large B-cell lymphomaVJHemOnc · 03/07/2026 · 2:06 · apoio da indústriaKey clinical outcomes for evaluating treatment success in myelofibrosisVJHemOnc · 03/07/2026 · 5:01 · apoio da indústriaSelecting patients with AML for transplant: key considerations & the role of enhanced MRD monitoringVJHemOnc · 03/07/2026 · 2:38 · apoio da indústriaReal-world data support olutasidenib after venetoclax in IDH1-mutated AMLVJHemOnc · 02/07/2026 · 2:33 · apoio da indústriaCould luspatercept modify disease in lower-risk myelodysplastic syndromes?VJHemOnc · 02/07/2026 · 2:57 · apoio da indústriaOptimizing anemia management in lower-risk myelodysplastic syndromesVJHemOnc · 02/07/2026 · 3:09 · apoio da indústria